ArticleJAMA2011
Use of radioactive iodine for thyroid cancer.
Article in JAMA, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 4 syntheses or guidelines pooled it, 189 citations in OpenAlex.
- Radioactive Iodine Ablation Can Reduce the Structural Recurrence Rate of Intermediate-Risk Papillary Thyroid Microcarcinoma: A Meta-Analysis.Computational and mathematical methods in medicine · 2022Pooled it
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2016Guideline
- The Effectiveness of Radioactive Iodine Remnant Ablation for Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis.World journal of surgery · 2016Pooled it
- Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2015Guideline
- Article
- Survival benefit of postoperative radioiodine therapy among patients with intermediate-risk differentiated thyroid carcinoma.Endocrine · 2024Article
- Racial-Ethnic Comparison of Treatment for Papillary Thyroid Cancer in the Military Health System.Annals of surgical oncology · 2024Article
- Recent Advances in Metal-Organic Frameworks and Their Derivatives for Adsorption of Radioactive Iodine.Molecules (Basel, Switzerland) · 2024Review
- Article
- Differential impact of hospital and community factors on breadth and depth of hospital population health partnerships.Health services research · 2024Article
- Physicians' preferencesfor radioiodine treatment of differentiated thyroid cancer in Brazil: an observational study.Archives of endocrinology and metabolism · 2024Observational
- Trends in radioactive iodine treatment after total thyroidectomy in Italy, 2001-2018.European thyroid journal · 2023Article
- Comparison of Radioactive Iodine Activities in Terms of Short- and Long-term Results in Ablation Therapy in Patients with Low-risk Differentiated Thyroid Cancer.Molecular imaging and radionuclide therapy · 2023Article
- Urinary iodine excretion after using povidone iodine or chlorhexidine gluconate for topical disinfectant in patients undergoing thyroidectomy due to thyroid carcinoma: When to do radio active iodine therapy?Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023Article
- Development of Anticancer Peptides Using Artificial Intelligence and Combinational Therapy for Cancer Therapeutics.Pharmaceutics · 2022Review
- Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000-2018).Thyroid : official journal of the American Thyroid Association · 2022Article
- Patterns of radioiodine use for differentiated thyroid carcinoma in Brazil: insights and a call for action from a 20-year database.Archives of endocrinology and metabolism · 2021Article
- Trends in Thyroid Surgery and Guideline-Concordant Care in the United States, 2007-2018.Thyroid : official journal of the American Thyroid Association · 2021Article
- Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients.BMC cancer · 2021Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
contextSubstantial uncertainty persists about the indications for radioactive iodine for thyroid cancer. Use of radioactive iodine over time and the correlates of its use remain unknown.
objectiveTo determine practice patterns, the degree to which hospitals vary in their use of radioactive iodine, and factors that contribute to this variation. DESIGN, SETTING, AND PATIENTS: Time trend analysis of radioactive iodine use in a cohort of 189,219 patients with well-differentiated thyroid cancer treated at 981 hospitals associated with the US National Cancer Database between 1990 and 2008. We used multilevel analysis to assess the correlates of patient and hospital characteristics on radioactive iodine use in the cohort treated from 2004 to 2008.
main outcome measureUse of radioactive iodine after total thyroidectomy.
resultsBetween 1990 and 2008, across all tumor sizes, there was a significant increase in the proportion of patients with well-differentiated thyroid cancer receiving radioactive iodine (1373/3397 [40.4%] vs 11,539/20,620 [56.0%]; P < .001). Multivariable analysis of patients treated from 2004 to 2008 found that there was a statistical difference in radioactive iodine use between American Joint Committee on Cancer stages I and IV (odds ratio [OR], 0.34; 95% confidence interval [CI], 0.31-0.37) but not between stages II/III and IV (for stage II vs stage IV, OR, 0.97; 95% CI, 0.88-1.07 and for stage III vs stage IV, OR, 1.06; 95% CI, 0.95-1.17). In addition to patient and tumor characteristics, hospital volume was associated with radioactive iodine use. Wide variation in radioactive iodine use existed, and only 21.1% of this variation was accounted for by patient and tumor characteristics. Hospital type and case volume accounted for 17.1% of the variation. After adjusting for available patient, tumor, and hospital characteristics, 29.1% of the variance was attributable to unexplained hospital characteristics.
conclusionAmong patients treated for well-differentiated thyroid cancer at hospitals in the National Cancer Database, there was an increase in the proportion receiving radioactive iodine between 1990 and 2008; much of the variation in use was associated with hospital characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.